The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Grace Cuddihy, Ellen K. Wasan, Yunyun Di, Kishor M. Wasan
Format:	Article
Language:	English
Published:	MDPI AG 2019-02-01
Subjects:	oral formulation amphotericin B fungal infections parasitic infections developing world drug delivery
Online Access:	https://www.mdpi.com/1999-4923/11/3/99